If you've been researching GLP-1 weight loss medications, you've probably encountered a confusing jumble of names: Zepbound, Mounjaro, tirzepatide, compounded tirzepatide. They're all related — but they're not all the same thing. Here's a clear breakdown of what each name means and how they connect.
The Short Answer
Yes — Zepbound is tirzepatide. Specifically, Zepbound is the brand name that Eli Lilly uses to market tirzepatide for weight management. Tirzepatide is the name of the actual drug molecule — the active pharmaceutical ingredient that makes the medication work.
Think of it like this: "ibuprofen" is the drug, "Advil" is the brand name. Tirzepatide is the drug, Zepbound is one of its brand names.
The Full Family of Tirzepatide Products
Eli Lilly manufactures tirzepatide and sells it under two different brand names for two different FDA-approved uses:
| Product | Active Drug | FDA-Approved For | Manufacturer |
|---|---|---|---|
| Mounjaro® | Tirzepatide | Type 2 Diabetes | Eli Lilly |
| Zepbound® | Tirzepatide | Chronic Weight Management | Eli Lilly |
| Compounded Tirzepatide | Tirzepatide | Not FDA-approved* | Licensed compounding pharmacies |
*Compounded medications are prepared by licensed pharmacies under state or federal oversight but are not individually evaluated or approved by the FDA.
Mounjaro was approved by the FDA in May 2022 for type 2 diabetes management. It was the first tirzepatide product on the market.
Zepbound was approved by the FDA in November 2023 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition.
The medication inside both products is identical — same tirzepatide molecule, same doses, same auto-injector delivery device. The only difference is the FDA-approved indication and the brand label on the box.
How Does Tirzepatide Work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. That means it activates two different hormone receptors in your body simultaneously:
GLP-1 (glucagon-like peptide-1): This is the same pathway targeted by semaglutide (Ozempic/Wegovy). GLP-1 receptor activation reduces appetite, slows stomach emptying, and helps regulate blood sugar.
GIP (glucose-dependent insulinotropic polypeptide): This is the additional pathway unique to tirzepatide. GIP receptor activation provides further metabolic benefits, including improved insulin sensitivity and effects on fat metabolism.
The dual mechanism is a key reason why tirzepatide showed higher average weight loss in clinical trials compared to semaglutide-based medications. In the SURMOUNT-1 trial, the highest dose of tirzepatide (15mg) produced average weight loss of approximately 21% of body weight — one of the highest numbers ever seen in a pharmaceutical weight loss trial.
What About Compounded Tirzepatide?
Compounded tirzepatide contains the same active ingredient (tirzepatide) as Zepbound and Mounjaro. The difference is who makes it and how it's regulated.
Brand-name Zepbound is manufactured by Eli Lilly in FDA-inspected facilities using their proprietary formulation and delivered in pre-filled auto-injector pens. It costs approximately $1,000–$1,080 per month without insurance.
Compounded tirzepatide is prepared by licensed compounding pharmacies using bulk tirzepatide API (active pharmaceutical ingredient). It typically comes in multi-dose vials rather than auto-injectors and costs approximately $250–$450 per month through most telehealth providers — a significant savings.
📋 Key Differences: Zepbound vs. Compounded
Same active ingredient: Both contain tirzepatide.
Different manufacturing: Zepbound is manufactured by Eli Lilly; compounded is prepared by individual pharmacies.
Different delivery: Zepbound uses auto-injector pens; compounded typically uses vials with syringes.
Different formulation: Inactive ingredients (buffers, preservatives) may differ.
Different FDA status: Zepbound is FDA-approved; compounded tirzepatide is not.
Different cost: Zepbound ~$1,000+/mo; compounded ~$250–$450/mo.
Why Does Zepbound Cost So Much More?
Several factors drive the price gap between brand-name Zepbound and compounded tirzepatide:
Research and development costs. Eli Lilly invested billions in developing tirzepatide, running clinical trials, and obtaining FDA approval. Brand-name pricing reflects recouping those investments.
Patent protection. Eli Lilly holds patents on tirzepatide that prevent generic manufacturers from producing it (though patent expiration timelines are approaching). Compounding pharmacies operate under a different legal framework — they're not producing "generic" tirzepatide but rather preparing individualized prescriptions.
Manufacturing and distribution. Eli Lilly's auto-injector pens, cold-chain distribution, and global supply chain add significant cost. Compounding pharmacies have much simpler operations.
Marketing. The direct-to-consumer advertising budget for Zepbound is enormous. Those costs are built into the price.
Is Compounded Tirzepatide as Effective as Zepbound?
When properly compounded at accurate concentrations by a quality pharmacy, compounded tirzepatide should deliver equivalent therapeutic effect — because it's the same molecule at the same dose. The mechanism of action doesn't change based on who prepares the medication.
The variable is quality assurance. Eli Lilly's manufacturing is standardized and FDA-inspected. Compounding pharmacy quality varies. This is why choosing a provider that partners with a PCAB-accredited compounding pharmacy is so important — it provides independent verification of potency, sterility, and quality standards.
Can You Switch Between Zepbound and Compounded Tirzepatide?
Many patients do switch between brand-name and compounded tirzepatide, typically in one of two scenarios:
Brand to compounded: Patients who started on Zepbound through insurance but lost coverage, had a formulary change, or simply want to reduce out-of-pocket costs. Since both are tirzepatide, the transition is usually straightforward — your provider simply prescribes compounded tirzepatide at the same dose you were taking.
Compounded to brand: Patients who started with compounded tirzepatide and later obtained insurance coverage for Zepbound. Again, same molecule — you continue at the same dose level.
In either case, discuss the switch with your healthcare provider. They may want to adjust monitoring or confirm dosing consistency during the transition.
Frequently Asked Questions
Is Mounjaro the same as Zepbound?
Same drug (tirzepatide), different FDA-approved indication. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. The medication is identical.
Can my doctor prescribe Mounjaro for weight loss instead of Zepbound?
Yes — this is called "off-label" prescribing, and it's legal and common. Some doctors and insurance plans may prefer one over the other for administrative or formulary reasons, but the medication is the same.
Is there a generic Zepbound?
Not yet. Eli Lilly holds patents on tirzepatide. True generic versions may become available when those patents expire, though the exact timeline is subject to ongoing legal proceedings. Compounded tirzepatide is not technically a "generic" — it's a compounded preparation of the same active ingredient.
Do I need a prescription for compounded tirzepatide?
Yes. Tirzepatide is a prescription medication regardless of whether it's brand-name or compounded. Any source selling it without a medical evaluation and prescription is operating outside the law.